SEP 8, 2026 · PHASE 2 TRIAL
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
ClinicalTrials.gov
Phase 2 interventional trial with planned safety and efficacy endpoints in EGFR-mutant NSCLC; no results reported in this registry record.
Reported
Planned enrollment60
PhasePhase 2
Primary outcome 1Number of participants with adverse events…